Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2025 · 10-Q
Revenue$9.23M$9.23M−23.3% vs Q2 2024 Net Income-$640.00K-$640.00KN/M vs Q2 2024 EPS Diluted-$0.14-$0.14N/M vs Q2 2024 Gross Profit$5,276,000−32.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$520,000−63.0% Margins · derivedGross margin57.1%−7.7 pt vs Q2 2024
Operating margin-5.1%−26.9 pt vs Q2 2024
Net margin-6.9%−27.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end